Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Uproleselan · 1 trial · 1 indication
To assess the pharmacokinetic profile in patients with relapsed/refractory AML.
To assess the pharmacokinetic profile in patients with relapsed/refractory AML.
To assess the pharmacokinetic profile in patients with relapsed/refractory AML.
To assess the pharmacokinetic profile in patients with relapsed/refractory AML.
Number of participants with an AE.
Number of participants could tolerate the Uproleselan combined with chemotherapy.
| Arm | Type | Description |
|---|---|---|
| A Phase I, open-labeled multicenter study | EXPERIMENTAL | Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC) |
| Name | Type | Description |
|---|---|---|
| Uproleselan | DRUG | A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin |
Inclusion Criteria: 1. ≥18 years and ≤60 years in age 2. AML (including secondary AML) diagnosed as per WHO standards (2008). 3. For refractory AML, only cytarabine/daunorubicin(or Idarubicin) as can be applied repeatedly(maximal twice) as induction, no other chemotherapy are allowed to be applied ...
Uproleselan is an investigational small molecule being studied for the treatment of relapsed or refractory acute myeloid leukemia (AML). It is administered in combination with chemotherapy. As of now, it is in Phase 1 clinical development and has not been approved by regulatory authorities.
Uproleselan is being developed by Apollomics Inc., a biopharmaceutical company. Apollomics is publicly traded on the Nasdaq under the ticker symbol APLM. The company is conducting clinical trials to evaluate the safety and pharmacokinetics of Uproleselan in patients with relapsed or refractory AML.
Uproleselan is currently in Phase 1 clinical development. A Phase 1 study has been completed, which evaluated the drug's pharmacokinetics and safety when combined with chemotherapy in Chinese patients with relapsed or refractory AML. The drug remains investigational and is not yet approved for any use.
Uproleselan has one completed Phase 1 clinical trial registered under NCT04839341. This study evaluated the pharmacokinetics and safety of Uproleselan combined with chemotherapy in 12 Chinese patients with relapsed or refractory AML. The trial was uncontrolled and not blinded.
Uproleselan is a small molecule designed to target E-selectin, a cell adhesion molecule that helps leukemia cells survive in the bone marrow. By blocking E-selectin, Uproleselan may make leukemia cells more vulnerable to chemotherapy. This mechanism is being investigated in the context of relapsed or refractory AML.